Hospira Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HOSPIRA, and when can generic versions of HOSPIRA drugs launch?
HOSPIRA has five hundred and twelve approved drugs.
There are nine US patents protecting HOSPIRA drugs.
There are sixty-seven patent family members on HOSPIRA drugs in thirty-eight countries and three hundred and seventy-nine supplementary protection certificates in sixteen countries.
Summary for Hospira
| International Patents: | 67 |
| US Patents: | 9 |
| Tradenames: | 328 |
| Ingredients: | 205 |
| NDAs: | 512 |
| Patent Litigation for Hospira: | See patent lawsuits for Hospira |
| PTAB Cases with Hospira as petitioner: | See PTAB cases with Hospira as petitioner |
Drugs and US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% | heparin sodium | INJECTABLE;INJECTION | 018911-007 | Jan 30, 1985 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Hospira | MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 020488-002 | Jul 11, 1995 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Hospira | GENTAMICIN SULFATE | gentamicin sulfate | INJECTABLE;INJECTION | 062420-001 | Aug 15, 1983 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Hospira | ALFENTANIL | alfentanil hydrochloride | INJECTABLE;INJECTION | 075221-001 | Oct 28, 1999 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Hospira | PROPOFOL | propofol | INJECTABLE;INJECTION | 077908-001 | Mar 17, 2006 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hospira
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hospira | TRACRIUM PRESERVATIVE FREE | atracurium besylate | INJECTABLE;INJECTION | 018831-001 | Nov 23, 1983 | 4,179,507 | See Plans and Pricing |
| Hospira | BRETYLOL | bretylium tosylate | INJECTABLE;INJECTION | 017954-001 | Approved Prior to Jan 1, 1982 | RE29618 | See Plans and Pricing |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 4,910,214*PED | See Plans and Pricing |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-002 | Mar 13, 2013 | 6,716,867*PED | See Plans and Pricing |
| Hospira | PRECEDEX | dexmedetomidine hydrochloride | INJECTABLE;INJECTION | 021038-001 | Dec 17, 1999 | 5,344,840 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOSPIRA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 4 mcg/mL, 50 mL and 100 mL vials | ➤ Subscribe | 2013-12-26 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Injection | 100 mcg/mL | ➤ Subscribe | 2009-04-08 |
| ➤ Subscribe | Injection | 4 mcg/mL, 20 mL vials | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
International Patents for Hospira Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2014088433 | See Plans and Pricing |
| European Patent Office | 3345599 | See Plans and Pricing |
| Japan | 2014058577 | See Plans and Pricing |
| Brazil | 112013008005 | See Plans and Pricing |
| Hong Kong | 1249429 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hospira Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2404919 | C02404919/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE (LUMACAFTOR); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65981 02.09.2016 |
| 1499331 | SPC/GB13/034 | United Kingdom | See Plans and Pricing | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 0266730 | SPC/GB97/005 | United Kingdom | See Plans and Pricing | PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926 |
| 1853250 | 2014C/037 | Belgium | See Plans and Pricing | PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230 |
| 2563920 | CA 2019 00001 | Denmark | See Plans and Pricing | PRODUCT NAME: A COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE HAVING A NUCLEOBASE SEQUENCE CONSISTING OF 20 LINKED NUCLEOSIDES ACCORDING TO EP B1 2563920 CLAIM 1 (SEQ ID NO: 80), ...SPECIFICALLY INOTERSEN; AND ITS DERIVATIVES, INCLUDING SODIUM SALTS ...; REG. NO/DATE: EU/1/18/1296 20180710 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
